Surrozen (SRZN)
(Delayed Data from NSDQ)
$8.44 USD
-0.56 (-6.22%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $8.40 -0.04 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SRZN 8.44 -0.56(-6.22%)
Will SRZN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SRZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRZN
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
SRZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
Other News for SRZN
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
Surrozen publishes study in 'eLife' on the proprietary SWEETS platform
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen presents preliminary results from Phase 1a study of SZN-043
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis